Demonstrating financial strength and strategic foresight, Syngene International Limited announced a robust Q1 performance with a 26% YoY increase in both revenues and profit after tax. This solid financial footing is propelling the company’s expansion initiatives.
Marking a key development, Syngene strengthened its position in the biologics contract development and manufacturing sector with the acquisition of a manufacturing facility from Stelis Biopharma Ltd. This facility brings an added 20,000 liters of biologics capacity to Syngene’s arsenal.
Adding to its strategic accomplishments, Syngene also received FDA approval for its API manufacturing facility in Mangalore. This certification acknowledges the high quality standards the company upholds, underscoring its dedication to operational excellence.
Signaling its focus on research services, Syngene has acquired additional land in Hyderabad. This acquisition represents the company’s commitment to invest in the future growth of its Research Services division.
